CSPC
CSPC
Biomedical R&D company
CSPC, founded in June, 1992 and headquartered in Shijiazhuang, is a biopharmaceutical developer. The founder is Cai Dongchen. Listed on the HKEX on June 21, 1994, the company's major shareholders are Massive Top. Limited. Rivals that have direct and indirect competition with CSPC include 111 Group, JD health, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
Briefing Jan 14, 2022 02:18 PM
· Healthcare
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
Briefing Jan 10, 2022 11:16 AM
· Healthcare
Lanjing microorganism completed a total of RMB 1.5 billion of Series B financing and accelerated the implementation of the "T-type" development strategy
In depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Jan 06, 2022 03:39 PM
· Healthcare
Xinmai medical announced strategic cooperation with rainbow medical, a famous medical device incubator in Israel
Briefing Jan 06, 2022 11:27 AM
· Healthcare
Hengrui medicine has been introduced for more than US $100 million! New antifungal drugs applied for listing in China
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Jan 06, 2022 09:28 AM
· Healthcare
Jiangsu new element medicine completed a round C financing of more than 300 million yuan, and the gout innovative medicine has a good curative effect
Briefing Jan 06, 2022 09:26 AM
· Healthcare
Jiayue pharmaceutical completed nearly 200 million yuan of B + round financing and promoted the mid and late stage clinical projects of innovative drug pipeline
Briefing Dec 31, 2021 06:27 PM
· Healthcare
The IPO of Lianying medical technology innovation board has been accepted by Shanghai Stock Exchange
Briefing Dec 31, 2021 05:55 PM
· Healthcare
Hengrui pharmaceutical CDK4 / 6 inhibitor approved! Treatment of advanced breast cancer
In depth
In depth
Briefing Dec 31, 2021 05:52 PM
· Healthcare
Hengrui pharmaceutical sglt-2 inhibitor hengglijing was approved in China
Briefing Dec 31, 2021 02:06 PM
· Healthcare
The first KRAS concomitant diagnostic PCR kit in China was approved for marketing
Briefing Dec 31, 2021 02:00 PM
· Healthcare
China's new crown oral drug vv116 has been authorized for emergency use in Uzbekistan
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Briefing Dec 31, 2021 01:57 PM
· Healthcare
Wu Kun, chief operating officer of Pfizer China, will leave
Briefing Dec 31, 2021 01:55 PM
· Healthcare
Samsung Bio said the acquisition of Bojian was untrue
Briefing Dec 30, 2021 08:58 AM
· Healthcare
Jdb175 and jdb153 tablets, a class I new drug of Jiabao Yaoyin, have been approved for clinical trial by China food and drug administration
Briefing Dec 29, 2021 09:18 PM
· Healthcare
For the treatment of male erectile dysfunction, yuekang pharmaceutical PDE5 inhibitor was approved for marketing
See more
Related Companies
EqualOcean Analysis
- Wuxi Apptec Embraces a More Health-Conscious China
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.